logo

For the Inventor, By the Inventor

Durham, NC, United States of America

Daniel T MacLeod

This inventor holds 14 USPTO granted patents and 13 published patent applications and 7 EPO patents, primarily in Genetically-Modified Cells. Top assignee: Precision Biosciences, Inc.. Active years: 2018-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel T MacLeod. Retrieved from https://idiyas.com/inventor/daniel-t-macleod

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.4

ph-index = 8

Forward Citations = 165(Granted Patents)


Company Filing History:

goldMedal14 out of 56 
 
Precision Biosciences, Inc.
 patents

Years Active: 2018-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Genetically-Modified Cells
Co-Stimulatory Domains
Engineered Meganucleases
Human T Cell Receptor
Nucleic Acids
Recognition Sequences
Gene Modification
T Cell Engineering
Immunotherapy
Cellular Engineering
Genetic Engineering
14 patents (USPTO):Explore Patents
1. 11286291 - Co-stimulatory domains for use in genetically-modified cells (2022-03-29),
2. 11268065 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2022-03-08),
3. 11266693 - Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene (2022-03-08),
4. 10800833 - Co-stimulatory domains for use in genetically-modified cells (2020-10-13),
5. 10799535 - Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene (2020-10-13),
6. 10093900 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-10-09),
7. 10093899 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-10-09),
8. 9993502 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-06-12),
9. 9993501 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-06-12),
10. 9969975 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-05-15),
11. 9950011 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-04-24),
12. 9950010 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-04-24),
13. 9889161 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-02-13),
14. 9889160 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2018-02-13),

Title: The Innovative Contributions of Daniel T. MacLeod

Introduction

Daniel T. MacLeod is a prominent inventor based in Durham, NC, known for his significant contributions to the field of genetic engineering. With a total of 14 patents to his name, MacLeod has made remarkable advancements in the development of genetically-modified cells and therapeutic applications.

Latest Patents

Among his latest patents, MacLeod has developed co-stimulatory domains for use in genetically-modified cells. This innovation promotes cell proliferation and cytokine secretion after antigen recognition. The disclosed genetically-modified cells incorporate a chimeric antigen receptor or an inducible regulatory construct that utilizes these co-stimulatory domains. Additionally, he has engineered nucleic acids encoding meganucleases that recognize sequences in the human T cell receptor alpha constant region gene. These recombinant meganucleases are pivotal in producing genetically-modified eukaryotic cells.

Career Highlights

MacLeod is currently associated with Precision Biosciences, Inc., where he continues to push the boundaries of genetic research. His work has been instrumental in developing novel therapeutic strategies aimed at combating diseases such as cancer.

Collaborations

Some of his notable coworkers include Derek Jantz and James Jefferson Smith, who collaborate with him on various innovative projects.

Conclusion

Daniel T. MacLeod's contributions to genetic engineering and his extensive patent portfolio underscore his role as a leading inventor in the field. His work continues to inspire advancements in medical science and therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…